Inflammatory Signal Inhibitors for COVID-19 (MATIS)

Conditions:   Coronavirus;   Covid19;   Pneumonia Interventions:   Drug: Ruxolitinib;   Drug: Fostamatinib;   Other: Standard of care Sponsors:   Imperial College London;   Imperial College Healthcare NHS Trust;   Rigel Pharmaceuticals;   Novartis Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials